+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Gene Therapy Market - Industry Outlook & Forecast 2022-2027

  • PDF Icon


  • 208 Pages
  • March 2022
  • Region: United States
  • Arizton
  • ID: 5562647
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this U.S. Gene Therapy Market Report

The market is witnessing steady growth due to the increased availability of funding from various public and private institutes. In addition, there is increased support from regulatory bodies for product approvals and providing fast-track designations to the products, which encourages vendors to manufacture the products at a faster rate.

U.S. gene therapy market is expected to grow at a CAGR of 43.44% during 2022-2027


  • Increasing Market Access for Gene Therapies
  • Introduction Of Universal Car-T Therapy
  • Increase In Strategic Acquisitions
  • Increased Funding For R&D Activities of Gene Therapies

The US gene therapy market would realize an absolute growth of over 771.00% in terms of revenue between 2021 and 2027.


Among product type segments, the CAR-T therapy segment dominates the US gene therapy market, accounting for a share of 51.96%, followed by non-CAR-T therapy with 48.04% in 2021.
Based on the vector type, the US gene therapy market is segmented into retroviral and others. The other segment includes adeno virus, adeno-associated virus, herpes simplex virus, and non-viral vectors. The retroviral segment accounted for a major share of 51.96% and others with 48.04% in 2021
Based on end-users, the market is segmented into hospitals, cancer care centers, and academic & research centers. The hospital segment dominated the market with a share of 56.45%, followed by cancer care centers with 35.87%.

Market Segmentation by Vector Type

  • Retroviral
  • Others

Market Segmentation by Product Type

  • Car T Therapy
  • Non-Car T Therapy

Market Segmentation by Indication

  • Oncology
  • Others

Market Segmentation by Gene Transfer

  • Ex-Vivo
  • In-Vivo

Market Segmentation by End User

  • Hospitals
  • Cancer Care Centers
  • Academic & Research Centers


The US gene therapy market is witnessing the high competition among the vendors. The market is characterized by the presence of various pharma and various small-scale companies. With the changing market landscape, the competition is turning intense due to some recent high-value M&As.

Key Vendors

  • Amgen
  • bluebird bio
  • Bristol Myers Squibb
  • Gilead Sciences
  • Novartis
  • F. Hoffmann-La Roche

Other Prominent Vendors

  • 4DMT
  • Abeona Therapeutics
  • AnGes
  • AskBio
  • Astellas Gene Therapies
  • Autolus Therapeutics
  • Candel Therapeutics
  • Castle Creek Biosciences
  • Cellectis
  • Evox Therapeutics
  • Freeline Therapeutics
  • Gene Biotherapeutics
  • Generation Bio
  • GenSight Biologics
  • Helixmith
  • Janssen Pharmaceuticals
  • Kolon Tissue Gene
  • Krystal Biotech
  • MeiraGTx
  • Orchard Therapeutics
  • Pfizer
  • Poseida Therapeutics
  • Passage Bio
  • RegenxBio
  • Sana Biotechnology
  • Sarepta Therapeutics
  • StrideBio
  • Solid Biosciences
  • VBL Therapeutics
  • Voyager Therapeutics
  • Uniqure


1. The analysis of the U.S. Gene Therapy market size and growth rate for the forecast period 2022-2027.
2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the U.S. Gene Therapy market.
3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
4. It offers a complete overview of market segments and the regional outlook of the Gene Therapy market.
5. The report offers a detailed overview of the vendor landscape, competitive analysis, and critical market strategies to gain competitive advantage.
Frequently Asked Questions about the U.S. Gene Therapy Market

What is the estimated value of the U.S. Gene Therapy Market?

The U.S. Gene Therapy Market was estimated to be valued at $1838.49 Million in 2022.

What is the growth rate of the U.S. Gene Therapy Market?

The growth rate of the U.S. Gene Therapy Market is 43.4%, with an estimated value of $16013.28 Million by 2027.

What is the forecasted size of the U.S. Gene Therapy Market?

The U.S. Gene Therapy Market is estimated to be worth $16013.28 Million by 2027.

Who are the key companies in the U.S. Gene Therapy Market?

Key companies in the U.S. Gene Therapy Market include Amgen, bluebird bio, Bristol Myers Squibb, Gilead Sciences, Novartis, F. Hoffmann, La Roche, 4DMT, Abeona Therapeutics and AnGes.

Table of Contents

1 Research Methodology2 Research Objectives3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.2 Base Year
4.3 Scope of the Study
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Background
7.2 Gene Therapy: An Overview
8 Reimbursement for Gene Therapy in US
8.1 Overview
9 Regulatory Scenario for Gene Therapy Products
9.1 Overview
9.2 Clinical Trial Process for Gene Therapy
10 Commercial Gene Therapy Products in US
10.1 Overview
11 Gene Therapy Products in Pipeline
11.1 Overview
12 Market Opportunities & Trends
12.1 Increasing Market Access for Gene Therapies
12.2 Introduction of Universal Car-T Therapy
12.3 Increase in Strategic Acquisitions
12.4 Increased Funding for R&D Activities of Gene Therapies
13 Market Growth Enablers
13.1 Increase in Cmos to Manufacture Gene Therapies
13.2 Increasing Target Patient Population
13.3 Product Launches & Regulatory Approvals
13.4 Regulatory Support & Special Designations for Gene Therapies
14 Market Restraints
14.1 High Cost of Gene Therapy Products
14.2 Limitations of Gene Therapy Products
14.3 Availability of Alternative Therapeutics & Withdrawal of Products
15 Market Landscape
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Five Forces Analysis
16 Vector Type
16.1 Market Snapshot & Growth Engine
16.2 Market Overview
16.3 Retroviral
16.4 Other Vectors
17 Product Type
17.1 Market Snapshot & Growth Engine
17.2 Market Overview
17.3 Car-T Therapy
17.4 Non-Car-T Therapy
18 Indication
18.1 Market Snapshot & Growth Engine
18.2 Market Overview
18.3 Oncology
18.4 Others
19 Gene Transfer
19.1 Market Snapshot & Growth Engine
19.2 Market Overview
19.3 Ex-Vivo
19.4 In-Vivo
20 End-Users
20.1 Market Snapshot & Growth Engine
20.2 Market Overview
20.3 Hospitals
20.4 Cancer Care Centers
20.5 Academic & Research Centers
21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
22 Key Company Profiles
22.1 Amgen
22.2 Bluebird Bio
22.3 Bristol Myers Squibb
22.4 Gilead Sciences
22.5 Novartis
22.6 F. Hoffmann-La Roche
23 Gene Therapy Investigational Companies
23.1 4Dmt
23.2 Abeona Therapeutics
23.3 Anges
23.4 Askbio
23.5 Astellas Gene Therapies
23.6 Autolus Therapeutics
23.7 Candel Therapeutics
23.8 Castle Creek Biosciences
23.9 Cellectis
23.10 Evox Therapeutics
23.11 Freeline Therapeutics
23.12 Gene Biotherapeutics
23.13 Generation Bio
23.14 Gensight Biologics
23.15 Helixmith
23.16 Janssen Pharmaceuticals
23.17 Kolon Tissue Gene
23.18 Krystal Biotech
23.19 Meiragtx
23.20 Orchard Therapeutics
23.21 Pfizer
23.22 Poseida Therapeutics
23.23 Passage Bio
23.24 Regenxbio
23.25 Sana Biotechnology
23.26 Sarepta Therapeutics
23.27 Stridebio
23.28 Solid Biosciences
23.29 Vbl Therapeutics
23.30 Voyager Therapeutics
23.31 Uniqure
24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
25 Quantitative Summary
25.1 Market by Vector Type
25.2 Market by Product Type
25.3 Market by Indication
25.4 Market by Gene Transfer
25.5 Market by End-User
26 Appendix
26.1 Abbreviations

Companies Mentioned

  • Amgen
  • bluebird bio
  • Bristol Myers Squibb
  • Gilead Sciences
  • Novartis
  • F. Hoffmann-La Roche
  • 4DMT
  • Abeona Therapeutics
  • AnGes
  • AskBio
  • Astellas Gene Therapies
  • Autolus Therapeutics
  • Candel Therapeutics
  • Castle Creek Biosciences


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.